FGF23 and myopathy: Specifically ANGPT2 [HR 1.45(95% CI 1.00-2.13)] more strongly in HFpEF and IGFBP7 [2.51(0.95-6.64)] more strongly in HFrEFand MYBPC3 [1.62(0.99-2.64)].<h4>Conclusion</h4>Among seven novel biomarker assays, higher MYBPC3 (reflecting muscle injury and myopathy) and FGF23 (endothelial dysfunction, oxidative stress) distinguished HFrEF from HFpEF.